Apolipoproten E appears to be new potential druggable target for Alzheimer's

Reviewed by James Ives, M.Psych. (Editor)Jun 13 2019

Apolipoproten E (apoeE) is a major genetic risk factor for the development of Alzheimer's disease, yet the protein tends to be understudied as a potential druggable target for the mind-robbing neurodegenerative disease.

Now a research team led by the University of South Florida Health (USF Health) Morsani College of Medicine reports that a novel apoE antagonist blocks apoE interaction with N-terminal amyloid precursor protein (APP). Moreover, this peptide antagonist, known as 6KApoEp, was shown to reduce Alzheimer's-associated beta amyloid (β-amyloid) accumulation and tau pathologies in the brain, as well as improving learning and memory in mice genetically engineered to mimic symptoms of Alzheimer's disease.

Many failed anti-amyloid therapies for Alzheimer's disease have been directed against various forms of the protein β-amyloid, which ultimately forms clumps of sticky plaques in the brain. The presence of these amyloid plaques is one of the major hallmarks of Alzheimer's disease.

The USF Health research findings suggests that disrupting apoE physical interaction with N-terminal APP may be a new disease-modifying therapeutic strategy for this most common type of dementia.

The preclinical study was published online May 2 in Biological Psychiatry.

For the first time, we have direct evidence that the N-terminal section of apoE itself acts as an essential molecule (ligand) to promote the binding of apoeE to the N-terminal region of APP outside the nerve cell. This receptor-mediated mechanism plays a role in the development of Alzheimer's disease. Overstimulation of APP by apoE may be an earlier, upstream event that signals other neurodegenerative processes contributing to the amyloid cascade."

Darrell Sawmiller, PhD, Study Lead Author, Assistant Professor in the USF Health Department of Psychiatry & Behavioral Neurosciences

"Initially we wanted to better understand how apoE pathologically interacts with APP, which leads to the formation of β-amyloid plaques and neuronal loss," said study senior author Jun Tan, PhD, MD, a professor in the USF Health Department of Psychiatry & Behavioral Neurosciences. "Our work further discovered an apoE derivative that can modulate structural and functional neuropathology in Alzheimer's disease mouse models."

Alzheimer's disease is a global epidemic, afflicting an estimated 50 million people worldwide and 5.8 million in the U.S, according to the Alzheimer's Association. With the aging of the Baby Boomer generation, the prevalence of the debilitating disease is expected to increase dramatically in the coming years. Currently, no treatments exist to prevent, reverse or halt the progression of Alzheimer's disease, and current medications may only relieve dementia symptoms for a short time.

Source:

University of South Florida (USF Innovation)

Journal reference:

Sawmiller, D. et al. (2019) A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces β-Amyloid-Associated Pathology, and Improves Cognition. Biological Psychiatry. doi.org/10.1016/j.biopsych.2019.04.026 .